1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 0559/07, NCT00803907
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: NCI, Other
Protocol IDs: H-2007-0252, PRMC_CO08303, NCT00994240
|
|
3.
|
Phase: Phase IV
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09US05N375-Gold, NCT01203878
|
|
4.
|
Phase: Phase IV
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-0933, NCT01229319
|
|
5.
|
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Mann-Cohen Version 2, NCT01459666
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: IPDTAKOTR/V06/28.12.11, NCT01538901
|
|
7.
|
Phase: Phase IV
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ISD-FPT-01-2012, NCT01656226
|
|
8.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H-1-2010-044, 2010-020179-22, NCT01260987
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: TROG 05.01, NCT00193895
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 01, NCT00663650
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2007.489/32, NCT00799188
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MEC 10-2-088, NCT01358045
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 50 to 75
Sponsor: Other
Protocol IDs: Carol2011, NCT01405144
|
|
14.
|
Phase: Phase III
Type: Prevention
Status: Active
Age: 40 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SP 488/2009, NCT01532453
|
|
15.
|
Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: oct-MM-2005, Grant # BIOPHOT 26-02-0020, NCT00390351
|
|
16.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6901 (5466), NCI-2011-01225, NCT01465815
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: CHORI-2007-016, UCSF-05862, R01-CA-109584, NCT00489086, 05862
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00226, 07070, N01CM62207, CDR0000576527, OSU-07070, 7813, NCT00563290
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DUSA-PDT-BCC-06, DUSA-PDT-BCC-06, NCT00747903
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 - 75
Sponsor: NCI
Protocol IDs: CHORI-2007-022, 05862, CHORI-H473-26042, NCT00783965
|
|
21.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
|
|
22.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Luc 09-002, NCT01129154
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0888, NCT01198028
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SHH4812g, GS01354, NCT01201915
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLDE225A2201, 2010-022629-14, NCT01327053
|
Mobile | Español
